GlassScriptPhysician profile
Shyla D Muriel
NPI 1558387571
$15,111.12
in general payments reported to CMS, 2019-2025
44 companies · $2,654 in 2025
The $2,654 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,039 · 2020: $1,967 · 2021: $1,340 · 2022: $1,689 · 2023: $3,296 · 2024: $3,126 · 2025: $2,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,075.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,822.38 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,849.45 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $1,365.89 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $1,360.93 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,106.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,025.07 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $837.89 | 2019-2025 | Jardiance, Ofev, Stiolto Respimat |
| Astellas Pharma US INC | $580.05 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $452.83 | 2019-2024 | Repatha, Otezla, Prolia |
| Sumitomo Pharma America, INC. | $429.03 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $350.77 | 2019-2025 | Steglatro, Belsomra, Steglujan |
| Takeda Pharmaceuticals U.S.A., INC. | $300.05 | 2019-2024 | Trintellix |
| Exact Sciences Corporation | $293.86 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $293.27 | 2022-2025 | Xifaxan |
| Allergan, INC. | $205.21 | 2020 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shyla Muriel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.